# MEDI8852 phase 1 study

## Treatment Emergent Adverse Events

participants

participants reported TEAEs



| 250mg | 750mg | 1500mg | 3000mg | Placebo |
|---|---|---|---|---|
| 66.7% | 40.0% | 30.0% | 16.7% | 37.5% |

## t ½ (days)

* Is the time required for the concentration of the drug in the body to be reduced by 50%




## Other safety results

Most reported TEAEs were hypoglycemia and headache

Results showed good concentration separation between 750 and 3000 mg

Mallory RM, et al., A phase 1 study to evaluate the safety and pharmacokinetics of MEDI8852, an anti-influenza A monoclonal antibody, in healhty adult volunteers, Biologicals (2017), http://dx.doi.org/10.1016/j.biologicals.2017.08.007

ClinBAY

MEDI8852 phase 1 study

## Treatment Emergent Adverse Events




## t ½ (days)

* Is the time required for the concentration of the drug in the body to be reduced by 50%




## Other safety results

Most reported TEAEs were hypoglycemia and headache

Results showed good concentration separation between 750 and 3000 mg

Mallory RM, et al., A phase 1 study to evaluate the safety and pharmacokinetics of MEDI8852, an anti-influenza A monoclonal antibody, in healhty adult volunteers, Biologicals (2017), http://dx.doi.org/10.1016/j.biologicals.2017.08.007